Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation

Gene Therapy

Volumn 4, Issue 9, 1997, Pages 943-949

  Czubayko, F ^a,b   Downing, S G ^a,b   Hsieh, S S ^a   Goldstein, D J ^a   Lu, P Y ^c   Trapnell, B C ^b,c   Wellstein, A ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenovirus; Gene therapy; HER 2 neu; Pleiotrophin; Ribozymes

Indexed keywords

PLEIOTROPHIN; PROTEIN TYROSINE KINASE; RIBOZYME;

ADENOVIRUS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

EID: 0030825068     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300483     Document Type: Article

References (32)

1. Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991; 64: 271-280.
2. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a bad influence. Cell 1996; 87: 589-592.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
4. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
5. Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am J Clin Pathol 1994; 102: S13-S24.
6. Pietras RJ et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-2446.
7. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-182.
8. Gusterson BA et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-1056.
9. Muss HB et al. c-erbB-2 Expression and response to adjuvant therapy in woman with node-positive early breast cancer. New Engl J Med 1994; 330: 1260-1266.
10. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
11. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
12. Warren RS et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. j Clin Invest 1995; 95: 1789-1797.
13. Czubayko F, Schulte AM, Berchem GJ, Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 1996; 93: 14753-14758.
14. Christoffersen RE, Marr JJ. Ribozymes as human therapeutic agents. J Med Chem 1995; 38: 2023-2037.
15. Couture LA, Stinchcomb DT. Anti-gene therapy: the use of ribozymes to inhibit gene function. Trends Genet 1996; 12: 510- 515.
16. Feng M et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55: 2024-2028.
17. Li M et al. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther 1996; 3: 221-229.
18. Scanlon KJ et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 1991; 88: 10591-10595.
19. Jarvis T et al. Inhibition of vascular smooth muscle proliferation by ribozymes that cleave c-Myb mRNA. RNA 1996; 2: 419-428.
20. Lieber A et al. Elimination of hepatitis c virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70: 8782-8791
21. Lieber A, Kay MA. Adenovirus-mediated expression of ribozymes in mice. J Virol 1996; 70: 3153-3158.
22. Czubayko F, Riegel AT, Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 1994; 269: 21358-21363.
23. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. BioTechnique 1988; 6: 616-624.
24. Greenberger JS et al. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil, basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci USA 1983; 80: 2931-2935.
25. Carraway III KL, Cantley LC. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 1994; 78: 5-8.
26. Fang W et al. Pleiotrophin stimulates fibroblasts, endothelial and epithelial cells, and is expressed in human cancer. J Biol Chem 1992; 267: 25889-25897.
27. Trapnell BC. Adenoviral vectors for gene transfer. Adv Drug Delivery Rev 1993; 12: 185-199.
28. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ (ed). Gene Transfer and Expression Protocols. Humana Press: Clifton, NJ, 1991, pp 109-128.
29. Chen SH et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
30. Lee CT et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 1996; 56: 3038-3041.
31. Mittereder N et al Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994; 5: 717-729.
32. Goldstein DJ et al. The bovine papillomavirus type l E5 transforming protein specifically binds and activates the β-type receptor for the platelet-derived growth factor but not other related tyrosine kinase-containing receptors to induce cellular transformation. J Virol 1994; 68: 4432-4441.